BRAF and melanoma: As such, numerous MEK inhibitors have been developed for clinical use (e.g. trametinib, cobimetinib, binimetinib) and dual BRAF and MEK inhibition is now considered the standard-of-care over BRAF inhibitor monotherapy for the treatment of BRAFV600 melanoma patients.